FDA’s Authority Over Lab-Developed Tests Overturned: What the Court’s Decision Means for Lab Testing
Previously, this blog covered the FDA’s decision to regulate lab-developed tests (LDTs) as medical devices. However, a ruling from a federal district court in Texas earlier this year has changed that.
EM debt typically commands a yield premium over Developed Market debt due to perceived higher risks. Adding EM debt to a core portfolio may enhance diversification across regions, credit qualities, ...
The US Food and Drug Administration (FDA) plans to scrutinize the safety and efficacy of lab-developed tests — those designed, manufactured, and used in a single laboratory — far more thoroughly in ...
Emerging markets equities can offer outsized potential and portfolio diversification benefits to investors for three reasons. First, emerging markets tend to exhibit a substantial demographic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results